Expression and Clinical Significance of P63 in HER2 Low-Expression Breast Cancer
-
Published:2023
Issue:12
Volume:13
Page:18644-18652
-
ISSN:2161-8712
-
Container-title:Advances in Clinical Medicine
-
language:
-
Short-container-title:ACM
Publisher
Hans Publishers
Subject
General Engineering
Reference70 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2. Erratum to “Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
3. HER2-Low Breast Cancer: Pathological and Clinical Landscape
4. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
5. Modi, S., Saura, C., Yamashita, T., et al. (2020) Abstract PD3-06: Updated Results from DESTINY-Breast01, a Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd ) in HER2 Positive Metastatic Breast Cancer. Cancer Research, 81, PD3-06.